Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates
26. Januar 2022 06:55 ET
|
Myovant Sciences, Inc.
Third fiscal quarter 2021 total revenues of $54.4 million, including net product revenue of $29.3 millionNet product revenue from U.S. sales of ORGOVYX® of $24.4 million, reflecting 40% sequential...
Myovant Sciences to Host Third Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on January 26, 2022
12. Januar 2022 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and...
Myovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021
10. Januar 2022 06:55 ET
|
Myovant Sciences, Inc.
Estimated total revenue of $54.0-$55.0 million, including net product revenue of $28.8-$29.8 millionEstimated ORGOVYX® net product revenue of $24.2-$24.6 million, reflecting 40% sequential volume...
Myovant Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
03. Januar 2022 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief...
Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference
23. November 2021 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the Evercore ISI 4th...
Nancy Valente, M.D. Joins Myovant Sciences’ Board of Directors
08. November 2021 06:00 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland and LONDON, United Kingdom, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced...
Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates
26. Oktober 2021 06:55 ET
|
Myovant Sciences, Inc.
Second fiscal quarter 2021 total revenues of $77.9 million; net product revenue from U.S. sales of ORGOVYX® of $18.7 million and MYFEMBREE® of $0.6 millionEstimated 8,000 cumulative patients treated...
Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
19. Oktober 2021 06:58 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland and NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced the presentation of new data from clinical studies of its...
Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021
12. Oktober 2021 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and...
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
09. September 2021 06:58 ET
|
Myovant Sciences, Inc.
Filing in endometriosis is supported by data from the Phase 3 SPIRIT programFDA PDUFA target action date is May 6, 2022 BASEL, Switzerland and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) --...